Scott Kathleen D. 4
4 · ARS Pharmaceuticals, Inc. · Filed May 22, 2025
Insider Transaction Report
Form 4
Scott Kathleen D.
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-05-20−50,000→ 752,330 totalExercise: $1.50Exp: 2032-02-29→ Common Stock (50,000 underlying) - Sale
Common Stock
2025-05-20$14.10/sh−50,000$705,165→ 7,424 total - Exercise/Conversion
Common Stock
2025-05-20$1.50/sh+50,000$75,000→ 57,424 total
Holdings
- 8,250(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Includes 2,475 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
- [F2]The weighted average sale price for the transaction reported was $14.1033 and the range of prices were between $14.10 and $14.115. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.